The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer

Simple item page
dc.contributor.authormutevelızade G.
dc.contributor.authorKocer N.E.
dc.contributor.authorReyhan M.
dc.date.accessioned2024-07-22T08:03:42Z
dc.date.available2024-07-22T08:03:42Z
dc.date.issued2022
dc.description.abstractObjective: This study aimed to investigate immunohistochemical staining of sodium iodide symporter (NIS) and its effect on response to I-131 therapy in differentiated thyroid carcinoma patients. Methods: We evaluated NIS expression, the intracellular distribution of NIS, iodine-131 uptake in residual tissues on post-ablation I-131 whole body scan, and the ablation status after 100 mCi I-131 therapy. We also investigated NIS expression and localization in tumoral paraffin-embedded tissues. Results: In this retrospective study, 35 patients (mean age 44.17 ± 12.9 years, 27 female, 8 male) were studied. Twenty-one of these patients responded to radioiodine therapy, and 14 did not. NIS expression and iodine-131 uptake in residual tissues post-ablation I-131 whole body scan were not statistically significant. When we compared the patients who responded to radioiodine therapy and the poor responder group, NIS expression and iodine-131 uptake in residual tissues did not demonstrate statistically significant difference [(p = 0.308) (p = 0.985) respectively]. 47.6% of the patients in the successful ablation group and 85.7% in the unsuccessful ablation group had intracellular NIS immunostaining. The difference was not statistically significant (p = 0.139). 52.4% of the patients in the successful ablation group and 7% in the unsuccessful ablation group had NIS immunostaining at the basolateral membrane. The difference was statistically significant (p < 0.05). Conclusions: In conclusion, we did not find any significant difference between successful and unsuccessful ablation groups in terms of NIS expression; however, we concluded that the intracellular (cytoplasmic) localization of NIS is one of the leading causes of ablation failure regardless of NIS expression in DTC patients. © 2022, The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
dc.identifier.DOI-ID10.1007/s12149-022-01794-w
dc.identifier.issn09147187
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12400
dc.language.isoEnglish
dc.publisherSpringer
dc.subjectAdenocarcinoma
dc.subjectAdult
dc.subjectFemale
dc.subjectHumans
dc.subjectIodine Radioisotopes
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRetrospective Studies
dc.subjectSymporters
dc.subjectThyroid Neoplasms
dc.subjectantibody
dc.subjectbuffer
dc.subjectdistilled water
dc.subjecthematoxylin
dc.subjectiodine
dc.subjectiodine 131
dc.subjectlevothyroxine
dc.subjectparaffin
dc.subjectradioactive iodine
dc.subjectsodium iodide symporter
dc.subjectthyrotropin
dc.subjectcotransporter
dc.subjectIodine-131
dc.subjectradioactive iodine
dc.subjectsodium iodide symporter
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectbasolateral membrane
dc.subjectcancer patient
dc.subjectcellular distribution
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdifferentiated thyroid cancer
dc.subjectdistant metastasis
dc.subjectdrug therapy
dc.subjectfemale
dc.subjectfollicular carcinoma
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectlack of drug effect
dc.subjectmale
dc.subjectmetastasis
dc.subjectprotein expression
dc.subjectprotein function
dc.subjectretrospective study
dc.subjectthyroid cancer
dc.subjectthyroid papillary carcinoma
dc.subjecttreatment failure
dc.subjectwhole body scintiscanning
dc.subjectyoung adult
dc.subjectadenocarcinoma
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectthyroid tumor
dc.titleThe effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu